HNB
SYRE icon

Huntington National Bank’s Spyre Therapeutics SYRE Stock Holding History

Huntington National Bank’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,470
Closed -$24.6K – 4218
2025
Q3 		$24.6K Hold
1,470
– – ﹤0.01% 1524
2025
Q2 		$22K Hold
1,470
– – ﹤0.01% 1533
2025
Q1 		$23.7K Hold
1,470
– – ﹤0.01% 1468
2024
Q4 		$34.2K Buy
+1,470
New +$43.1K ﹤0.01% 1360

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Huntington National Bank's SYRE Position: Q4 2025 in Review

Huntington National Bank sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 1,470 shares — an estimated $24.6K sold.

Huntington National Bank first reported a position in SYRE in Q4 2024 and held it in 4 quarters. The position peaked at $34.2K in Q4 2024. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Huntington National Bank reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Huntington National Bank sold 1,470 Spyre Therapeutics shares in Q4 2025, an estimated $24.6K.
  • Huntington National Bank first reported a position in Spyre Therapeutics in Q4 2024 and held it in 4 quarters.
  • Huntington National Bank's Spyre Therapeutics position peaked at $34.2K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Huntington National Bank's 13F filing for Q4 2025, filed 9 Feb 2026.